financetom
Business
financetom
/
Business
/
Market Chatter: Seven & i Will Split Into Two to Fend Off Couche-Tard Takeover
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Seven & i Will Split Into Two to Fend Off Couche-Tard Takeover
Oct 10, 2024 10:59 PM

08:25 AM EDT, 10/10/2024 (MT Newswires) -- Seven & i Holdings Co. is embarking on its biggest-ever overhaul, betting that a bold breakup will help fend off an unsolicited takeover proposal from a smaller rival and make up for a sluggish profit outlook, Bloomberg is reporting Thursday.

"We are going to speed up our transformation," Chief Executive Officer Ryuichi Isaka said in his first remarks since an buyout approach from Canada's Alimentation Couche-Tard Inc. ( ANCTF ) became public in August. Seeking to restore profitability and focus more on convenience stores, Isaka laid out a major revamp: "This plan is designed to bring out our strengths and achieve greater growth."

Bloomberg noted Seven & i essentially unveiled a plan to split in two: One business would be focused on 7-Eleven, convenience stores and gasoline stations, and the other would be a collection of 31 less profitable retail operations that might bring in strategic partners and eventually be listed separately. The big question, Bloomberg said, is if the move will be enough to win over any investors warming to Couche-Tard's approach.

The potentially problematic backdrop to potential deal negotiations is that Seven & i's core convenience store business is weakening, and it's unclear if the retailer, which will also rename itself 7-Eleven Corp. has a plan to address that, Bloomberg added.

(Market Chatter news is derived from conversations with market professionals globally, and/or from other media sources. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing Says Departing Chief Executive Received $32.8 Million Pay Package in 2023
Boeing Says Departing Chief Executive Received $32.8 Million Pay Package in 2023
Apr 8, 2024
08:21 AM EDT, 04/08/2024 (MT Newswires) -- Boeing's ( BA ) departing Chief Executive David Calhoun received a total compensation of about $32.8 million in 2023, up from his $22.6 million pay package in 2022, according to a regulatory filing Friday. Calhoun, who announced his resignation from the company in March amid concerns about Boeing ( BA ) planes' quality,...
Model N to Be Acquired by Vista Equity Partners for $1.25 Billion in Cash
Model N to Be Acquired by Vista Equity Partners for $1.25 Billion in Cash
Apr 8, 2024
08:22 AM EDT, 04/08/2024 (MT Newswires) -- Vista Equity Partners has entered into a definitive merger agreement to acquire Model N ( MODN ) , for $1.25 billion in an all-cash transaction, Model N ( MODN ) said Monday. Price: 29.49, Change: +2.4, Percent Change: +8.86 ...
Blackstone to take Apartment Income REIT private for $10 bln, WSJ reports
Blackstone to take Apartment Income REIT private for $10 bln, WSJ reports
Apr 8, 2024
April 8 (Reuters) - Asset manager Blackstone is taking private rental housing firm Apartment Income REIT ( AIRC ) , known as AIR Communities, for $10 billion in cash, the Wall Street Journal reported on Monday, citing people familiar with the matter. (Reporting by Ananta Agarwal in Bengaluru; Editing by Arun Koyyur) ...
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
Apr 8, 2024
08:22 AM EDT, 04/08/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) and Legend Biotech ( LEGN ) said the US Food and Drug Administration has approved Carvykti to treat adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. In 2017, Legend entered into a worldwide license and collaboration agreement with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved